Otsuka Holdings Co Ltd (4578.T)
5,302JPY
20 Apr 2018
¥-35 (-0.66%)
¥5,337
¥5,333
¥5,352
¥5,293
924,500
1,149,280
¥5,568
¥4,290
About
Overall
| Beta: | 0.44 |
| Market Cap(Mil.): | ¥2,513,607.00 |
| Shares Outstanding(Mil.): | 557.84 |
| Dividend: | 50.00 |
| Yield (%): | 2.22 |
Financials
| 4578.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 28.71 | 30.95 | 32.74 |
| EPS (TTM): | 156.94 | -- | -- |
| ROI: | 4.42 | 14.84 | 14.38 |
| ROE: | 5.21 | 16.34 | 16.07 |
BRIEF-Otsuka Pharmaceutical Says Co, X-Chem Have Signed Collaborative Research Agreement To Advance Discovery Process For New Otsuka Drug Compounds
* OTSUKA PHARMACEUTICAL SAYS CO, X-CHEM INC HAVE SIGNED COLLABORATIVE RESEARCH AGREEMENT TO ADVANCE DISCOVERY PROCESS FOR NEW OTSUKA DRUG COMPOUNDS Source text for Eikon: Further company coverage:
BRIEF-Otsuka Holdings to transfer medical device business to unit
* Says co plans to transfer medical device business to co's wholly owned unit Otsuka Medical Devices Co Ltd, with effective date of Jan. 1, 2018
BRIEF-FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD
* FDA accepts Otsuka's resubmission to support a regulatory review of Tolvaptan in the treatment of ADPKD
BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults
* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults Source text for Eikon: Further company coverage:
BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type
* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018
Estimates